Inhibikase Therapeutics (IKT) Other Accumulated Expenses (2020 - 2025)
Historic Other Accumulated Expenses for Inhibikase Therapeutics (IKT) over the last 6 years, with Q3 2025 value amounting to $116166.0.
- Inhibikase Therapeutics' Other Accumulated Expenses rose 79016.09% to $116166.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $116166.0, marking a year-over-year increase of 79016.09%. This contributed to the annual value of $81000.0 for FY2024, which is 2121.93% down from last year.
- According to the latest figures from Q3 2025, Inhibikase Therapeutics' Other Accumulated Expenses is $116166.0, which was up 79016.09% from $74316.0 recorded in Q2 2025.
- In the past 5 years, Inhibikase Therapeutics' Other Accumulated Expenses ranged from a high of $3.1 million in Q3 2022 and a low of $3322.0 during Q1 2021
- In the last 5 years, Inhibikase Therapeutics' Other Accumulated Expenses had a median value of $25561.0 in 2024 and averaged $622383.5.
- Per our database at Business Quant, Inhibikase Therapeutics' Other Accumulated Expenses soared by 2656217.23% in 2022 and then crashed by 9960.0% in 2024.
- Inhibikase Therapeutics' Other Accumulated Expenses (Quarter) stood at $5127.0 in 2021, then surged by 93.49% to $9920.0 in 2022, then surged by 936.46% to $102817.0 in 2023, then fell by 21.22% to $81000.0 in 2024, then skyrocketed by 43.41% to $116166.0 in 2025.
- Its last three reported values are $116166.0 in Q3 2025, $74316.0 for Q2 2025, and $127703.0 during Q1 2025.